Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SAN DIEGO, Oct. 17, 2016 -- SENTÉ, a privately held specialty aesthetics company pioneering the development of differentiated medical grade skincare products based on the science of glycosaminoglycan’s, today announced that the company has received a new patent grant, Process For The Purification Of Heparan Sulfate And Use Thereof In Cosmetological And Dermatological Preparations (U.S. Patent No. 9,4330,099) by the United States Patent and Trademark Office (USPTO). The company’s patent estate has now produced patents in Europe and the United States, further strengthening its ability to distribute innovative skin care products worldwide.
“The issuance of this patent is a major milestone for the company and comes at a time when we are gaining significant traction,” said Laurent Combredet, Chief Executive Officer. “This further solidifies our IP position and adds to our vision of becoming a leading aesthetics company dedicated to pioneering glycosaminoglycan science.”
“Our focus is to remain dedicated to the development of products based on rigorous science and clinical research,” said Faheem Hasnain, Chairman of the Board of Directors. “This patent grant allows us to continue developing innovative and market disrupting technologies in the US and abroad.”
About SENTÉ:
SENTÉ is a privately held specialty aesthetics company leveraging its expertise and foundation in biotechnology to deliver novel, science-based skin care products. SENTÉ is a recognized leader in the development of innovative and targeted medical skincare products based on glycosaminoglycans. Founded in 2007 and based in San Diego, California, further information may be found at http://sentelabs.com/. SENTÉ products are available through its exclusive network of physicians and medically supervised spas.
Media Contact: Creative Media Marketing Danielle Hale [email protected] p: 212.979.8884 ext. 213
